Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.

about

Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.

Item

http://www.wikidata.org/entity/Q50997883

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Donor-Specific Anti-Human Leuk ...... ing Tacrolimus and Everolimus.

@en

Donor-Specific Anti-Human Leuk ...... ing Tacrolimus and Everolimus.

@nl

type

Item

label

Donor-Specific Anti-Human Leuk ...... ing Tacrolimus and Everolimus.

@en

Donor-Specific Anti-Human Leuk ...... ing Tacrolimus and Everolimus.

@nl

prefLabel

Donor-Specific Anti-Human Leuk ...... ing Tacrolimus and Everolimus.

@en

Donor-Specific Anti-Human Leuk ...... ing Tacrolimus and Everolimus.

@nl

P1476

Donor-Specific Anti-Human Leuk ...... ving Tacrolimus and Everolimus

@en

P2093

Adrieli Bessa

http://www.w3.org/2001/XMLSchema#string

Alexandra Ferreira

http://www.w3.org/2001/XMLSchema#string

Claudia Felipe

http://www.w3.org/2001/XMLSchema#string

Erika Campos

http://www.w3.org/2001/XMLSchema#string

Geovana Basso

http://www.w3.org/2001/XMLSchema#string

Helio Tedesco-Silva

http://www.w3.org/2001/XMLSchema#string

Henrique Proença

http://www.w3.org/2001/XMLSchema#string

Juliana Mansur

http://www.w3.org/2001/XMLSchema#string

Laila Viana

http://www.w3.org/2001/XMLSchema#string

Maria Gerbase-DeLima

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.

Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials.

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.

Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications.

Through a glass darkly: seeking clarity in preventing late kidney transplant failure

The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study.

Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.

Eight-year results of the Spiesser study, a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation.

Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus.

Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness.

P304

497-508

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000475888

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jose Osmar Medina Pestana

José O Medina Pestana

P577

2017-05-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28511172

http://www.w3.org/2001/XMLSchema#string